RE:RE:RE:RE:RE:RE:RE:Interim Data... Infinity ... I think you have a lot confused.
A jv doesn't give control of the company to the big pharma. Only rights to the drug, for a specific indication, as per the jv contract. Big difference and basic concept that we should have understood.
By the way, it is TLT that has decided to seek interest of big pharmas for a jv. So Roger is not trying to withhold anything here. He's ok with that. Otherwise he wouldn't have been named CEO 3 weeks after the Board decision to hire Dr. Lliaba with a mandate to seek a jv. So I don't know why you don't even master the order of these 2 events and what they mean (everybody is aligned on the same jv objective)
And I don't know why he wouldn't as it would mark a key milestone over his 15y of hard work by making his innovation becoming a reality, by finally attracting a big pharma. And his 10M+ shares would immediately benefit of such valuation.
So there's no plot theories here. Just you having a strange reading on what TLT is executing on and that was clearly announced and that is in the normal scheme of things, at this stage, for any biotech.
_________
Infinity - (8/29/2023 11:20:52 PM)
RE:RE:RE:RE:RE:RE:Interim Data...
Socks and blonds and other pumpers like sci fart may feel that ONE man show is better than a JV and that the market has valued the stock at less than 30 cents is the correct valuation for the company based on the clinical data so far. He or She or it or they may have their own their reasons that defies all Logic for simply extending all deadlines. Today's News report will prop the stock price for sometime till RDW decides on a next PP at 25 cents which will bring the market price down. Is this truly better than a JV and RDW losing control of the company to a JV partner who will ultimately be accountable to the share holders?